Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole and Gefitinib in ER+ Metastatic Breast Cancer
NCT00049062Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Sep 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in breast cancer, sponsored by UT Health San Antonio. Primary endpoint: Objective Response Rate or Stable Disease at 6 months. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00049062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049062.